<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872299</url>
  </required_header>
  <id_info>
    <org_study_id>FP7/2007-2013, No. 241558</org_study_id>
    <secondary_id>241558</secondary_id>
    <nct_id>NCT01872299</nct_id>
  </id_info>
  <brief_title>Studies Investigating Co-morbidities Aggravating Heart Failure</brief_title>
  <acronym>SICA-HF</acronym>
  <official_title>Studies Investigating Co-morbidities Aggravating Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Hull</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moscow State University of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Siberian Branch of the Russian Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Russian Cardiology Research and Production Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University Clinic of Pulmonary and Allergic Diseases Golnik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Silesian Centre for Heart Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SICA-HF is a prospective, multicentre, multinational, longitudinal, pathophysiological
      evaluation study, which is being conducted in 11 centres across six countries. SICA-HF
      receives funding from the European commission's Seventh Framework Programme (FP7/2007-2013)
      under grant agreement no. 241558 (SICA-HF) and from the Russian Ministry of Science and
      Education within the file transfer protocol &quot;R&amp;D in priority fields of the S&amp;T complex of
      Russia 2007-2012&quot; under state contract number 02.527.11.0007. The aim of SICA-HF is to
      provide detailed characteristics of co-morbidities of heart failure at baseline and over
      time, particularly with regards to obesity, cachexia, and type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SICA-HF, consisting of outstanding European heart failure clinicians and basic researchers,
      has accomplished to provide a common platform for the two different research teams. All
      partners of SICA-HF recruited more than 1462 patients with chronic heart failure, 199
      patients with type 2 diabetes without heart failure, and 173 healthy control subjects. Thus,
      during the last year, a cumulative 91.4% of the target value was achieved for patients with
      chronic heart failure, 66.3% of the target value for diabetic controls, and 115.3% and thus
      over-achieving for healthy subjects. The data of all participating centers were collected and
      entered into the central database. As of this writing, 1469 of all chronic heart failure
      patients' visits, 255 of diabetic controls' visits, and 167 healthy controls' visits have
      been entered into the online database. In total, 171 patients have been reported to be
      deceased; the total number of hospitalizations is 2232.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>Prevalence, incidence, persistence and phenotype of obesity, cachexia and type 2 diabetes in patients with chronic heart failure.</measure>
    <time_frame>March 31, 2014</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in exercise capacity and cardiorespiratory reflex control</measure>
    <time_frame>March 31, 2014</time_frame>
    <description>To describe patterns of exercise capacity and cardiorespiratory reflex control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of body composition and its changes over time</measure>
    <time_frame>March 31, 2014</time_frame>
    <description>To analyse body composition and its changes over time in patients with chronic heart failure and type 2 diabetes, obesity or cachexia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and prevalence of sleep-disordered breathing and its impact on the clinical severity in patients with chronic heart failure</measure>
    <time_frame>March 31, 2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of impaired vascular reactivity on impaired skeletal muscle metabolic and functional capacity, including its underlying mechanisms</measure>
    <time_frame>March 31, 2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of metabolic status in patients with heart failure and type 2 diabetes, obesity and cachexia</measure>
    <time_frame>March 31, 2014</time_frame>
    <description>To describe the interplay and metabolic signalling pathways between adipose tissue, skeletal muscle, the bone marrow and the heart in patients with heart</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">1600</enrollment>
  <condition>Heart Failure</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy control subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart failure without co-morbidities</arm_group_label>
    <description>Patients with a clinical diagnosis of chronic heart failure without co-morbidities</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart failure with co-morbidities</arm_group_label>
    <description>Patients with a clinical diagnosis of chronic heart failure with co-morbidities</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetes mellitus</arm_group_label>
    <description>Patients with type 2 diabetes mellitus and without heart failure</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, plasma, DNA, biopsies from fat and muscle.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients and controls will be recruited from hospitals' outpatients' departments and/or via
        advertisements; in-patients are permitted if clinically stable.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Clinical diagnosis of heart failure;

          -  Objective evidence of cardiac dysfunctions as evidenced by at least ONE of the
             following:

               -  left ventricular ejection fraction ≤ 40%;

               -  left atrial dimension &gt;4.0 cm (or &gt;2.5 cm/m in height)

               -  NT-proBNP &gt;400 pg/ml [&gt;47.3 pmol/l] (or BNP &gt;150 pg/ml)

          -  Current treatment with loop diuretics;

          -  Age &gt;18 years;

          -  Willingness to provide informed consent

        Exclusion criteria:

          -  Congenital heart disease;

          -  Any life-threatening disease other than heart failure;

          -  Active malignancy of any type, or history of a malignancy within previous 5 years;

          -  Previous heart transplantation;

          -  Intra-venous therapy for heart failure given within the previous 72 hours;

          -  Severe neuro-muscular disease;

          -  History of unstable angina, myocardial infarction or stroke within 3 months prior to
             the study;

          -  Pregnancy;

          -  Treatment with immunosuppressive therapy, e.g. steroids for rheumatoid arthritis or
             obstructive lung disease;

          -  Significant renal dysfunction, defined as serum creatinine &gt;250 μmol/L [&gt;2.8 mg/dL];

          -  Severe liver disease, defined as any liver function tests &gt;3 times the upper limit of
             normal;

          -  Unable to understand and comply with protocol or to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan D Anker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité- University Medicine Berlin, Campus Virchow Klinikum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan von Haehling, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Charité- University Medicine Berlin, Campus Virchow Klinikum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Cleland, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Hull</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piotr Ponikowski, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Wroclaw Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Rosano, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>IRCCS San Raffaele</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Jordan, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugeniy Shlyakhto, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Almazov Federal Center for Heart, Blood &amp; Endocrinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vsevolod Tkachuk, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Lomonosov Moscow State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rostislav Karpov, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yelena Parfyonova, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Russian Cardiology Research and Production Complex</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitja Lainscak, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Clinic of Respiratory and Allergic diseases Golnik</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piotr Rozentryt, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Silesian Centre for Heart Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité- University Medicine Berlin, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Rom</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wroclaw, Medical University</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesian Centre for Heart Diseases</name>
      <address>
        <city>Zabrze</city>
        <zip>41800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lomonosov Moscow State University</name>
      <address>
        <city>Moscow</city>
        <state>Moskow</state>
        <zip>119192</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Cardiology Research and Production Complex</name>
      <address>
        <city>Moscow</city>
        <zip>12552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov Federal Center for Heart, Blood &amp; Endocrinology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic of Respiratory and Allergic diseases Golnik</name>
      <address>
        <city>Golnik</city>
        <zip>4204</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of HULL</name>
      <address>
        <city>Hull</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>von Haehling S, Lainscak M, Doehner W, Ponikowski P, Rosano G, Jordan J, Rozentryt P, Rauchhaus M, Karpov R, Tkachuk V, Parfyonova Y, Zaritskey AY, Shlyakhto EV, Cleland JG, Anker SD. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):187-194. Epub 2010 Dec 17.</citation>
    <PMID>21475696</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Prof. Stefan D Anker</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

